ZAG Inhibitors
The chemical class referred to as ZAG inhibitors encompasses a diverse array of compounds that exert their modulatory effects through the indirect inhibition of ZAG functions, particularly those related to lipid metabolism and energy homeostasis. This group includes compounds that target various aspects of cellular metabolism, such as glycolysis, fatty acid oxidation, and energy regulation. Compounds like Metformin, AICAR, and Phenformin activate AMPK, a key regulator of cellular energy status, which in turn can disrupt the lipolytic function of ZAG. By enhancing cellular uptake and utilization of fatty acids, these compounds can reduce the necessity of ZAG-mediated lipid mobilization from adipose tissue.
Additionally, inhibitors like Orlistat directly target lipase enzymes, thereby impeding the hydrolysis of triglycerides into free fatty acids and glycerol, which are substrates for ZAG's action. Others, such as Etomoxir and Perhexiline, directly inhibit enzymes involved in fatty acid oxidation, thereby reducing the substrate availability for ZAG-mediated lipid oxidation processes. Oxamate and 2-Deoxy-D-glucose exert their inhibitory effects by disrupting glycolysis and the Warburg effect, respectively, altering the metabolic milieu in which ZAG operates. Niclosamide, by uncoupling oxidative phosphorylation, alters the energy landscape of the cell, which could negate ZAG's metabolic functions. Sulfasalazine's impact on inflammation-associated metabolic pathways offers another avenue for modulating ZAG activity, given the protein's involvement in inflammation-related metabolic alterations. Berberine and α-lipoic acid, through their activation of AMPK, contribute to a cellular environment that is less conducive to the lipid-mobilizing activity of ZAG. Collectively, these chemicals form a class that can indirectly attenuate the biological activities of ZAG, primarily through the modulation of lipid metabolism and cellular energy homeostasis.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
Metformin modulates AMP-activated protein kinase (AMPK) activity, which is involved in the regulation of lipid metabolism. ZAG is known to play a role in lipid mobilization. By activating AMPK, metformin can lead to a decrease in lipolysis, which can negatively impact ZAG's function in promoting lipid degradation in adipocytes. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR is an AMPK activator that can mimic cellular energy depletion. Activation of AMPK by AICAR results in altered lipid metabolism, potentially countering ZAG’s lipolytic activity by promoting cellular uptake and utilization of fatty acids, thereby inhibiting ZAG’s role in the mobilization of lipids. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide uncouples mitochondrial oxidative phosphorylation, altering cellular energy metabolism. This action can indirectly influence ZAG function by disrupting the normal metabolic processes that ZAG is implicated in, particularly lipid metabolism and energy homeostasis. | ||||||
Oxamic acid | 471-47-6 | sc-250620 | 25 g | $148.00 | ||
Oxamate inhibits lactate dehydrogenase, interfering with the Warburg effect and potentially modulating the tumor microenvironment. As ZAG is implicated in cancer cachexia and altered metabolism, oxamate’s impact on metabolism can indirectly inhibit ZAG's function related to the abnormal metabolic processes observed in cancer. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose is a glycolysis inhibitor that interferes with glucose metabolism. Since ZAG is involved in energy balance and metabolism, altering glycolysis can indirectly inhibit ZAG by disrupting the energy balance within cells, potentially affecting ZAG-mediated processes. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Etomoxir inhibits carnitine palmitoyltransferase-1 (CPT-1) and fatty acid oxidation. ZAG is thought to enhance lipid mobilization and fatty acid oxidation. By inhibiting CPT-1, etomoxir can indirectly reduce ZAG's ability to mobilize fatty acids for beta-oxidation. | ||||||
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Perhexiline inhibits mitochondrial carnitine palmitoyltransferase (CPT) activity, which can reduce fatty acid oxidation. ZAG has a role in promoting the mobilization and utilization of lipids; therefore, perhexiline can potentially decrease ZAG's function by limiting the substrate availability for lipid oxidation. | ||||||
Lipase Inhibitor, THL | 96829-58-2 | sc-203108 | 50 mg | $52.00 | 7 | |
THL is a lipase inhibitor which can reduce fat absorption and alter lipid metabolism. ZAG is known to be associated with lipid mobilization, and by inhibiting lipases, orlistat could indirectly reduce ZAG’s lipolytic effect by decreasing the breakdown and subsequent mobilization of fat stores. | ||||||
Sulfasalazine | 599-79-1 | sc-204312 sc-204312A sc-204312B sc-204312C | 1 g 2.5 g 5 g 10 g | $61.00 $77.00 $128.00 $209.00 | 8 | |
Sulfasalazine impacts purine metabolism and has been shown to inhibit NF-κB, which may modulate inflammation-associated metabolic pathways. Through this mechanism, sulfasalazine could indirectly affect ZAG’s role in inflammation-related metabolic alterations. | ||||||
Phenformin Hydrochloride | 834-28-6 | sc-219590 | 10 g | $119.00 | 4 | |
Phenformin is another biguanide like metformin, which activates AMPK. It has a similar modulatory effect on lipid metabolism, thereby potentially reducing the lipolytic activity of ZAG through the activation of energy regulatory pathways. | ||||||